J Affect Disord:过敏性鼻炎能够增加年轻人的突发恐慌症风险

2019-04-28 AlexYang MedSci原创

已经有研究报道了过敏与恐慌症之间的相关性。然而,很少有研究探索过敏性鼻炎和恐慌症之间的关系。之前的研究受限于代表性设计、自我报道症状和匹配对照的缺乏以及类固醇影响和并发症考虑的欠缺。最近,有研究人员在一个大的年轻人群体中探索了过敏性鼻炎与恐慌症之间的纵向相关性。研究包括了1998年到2012年的79917个过敏性鼻炎案例。参与者的年龄均小于20岁,且1个案例匹配1名年龄、性别、居住地和保险费匹配的

已经有研究报道了过敏与恐慌症之间的相关性。然而,很少有研究探索过敏性鼻炎和恐慌症之间的关系。之前的研究受限于代表性设计、自我报道症状和匹配对照的缺乏以及类固醇影响和并发症考虑的欠缺。最近,有研究人员在一个大的年轻人群体中探索了过敏性鼻炎与恐慌症之间的纵向相关性。

研究包括了1998年到2012年的79917个过敏性鼻炎案例。参与者的年龄均小于20岁,且1个案例匹配1名年龄、性别、居住地和保险费匹配的对照。研究人员对2个小组的恐慌症进行了跟踪调查,直到2013年末结束。研究人员通过Cox回归分析进行了相关分析,并调整了性别、年龄、居住地、保险费、全身类固醇、哮喘、过敏性皮炎、过敏性结膜炎、注意缺陷多动障碍、抑郁、Charlson指数等变量。研究发现,在调整了其他变量后,过敏性鼻炎与恐慌症风险2倍的增加相关。其他恐慌症的独立风险因子为女性性别、更大的年龄和抑郁。

最后,研究人员指出,过敏性鼻炎与恐慌症风险的增加相关。恐慌症年轻人中过敏性鼻炎的评估和干预非常关键。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779426, encodeId=82001e7942665, content=<a href='/topic/show?id=48dc20680a' target=_blank style='color:#2F92EE;'>#Affect#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2068, encryptionId=48dc20680a, topicName=Affect)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Tue Dec 31 00:09:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784411, encodeId=4fba1e8441111, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Apr 30 07:09:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012995, encodeId=b067201299574, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Dec 09 03:09:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047108, encodeId=a28b204e10824, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Dec 27 12:09:00 CST 2019, time=2019-12-27, status=1, ipAttribution=)]
    2019-12-31 chenwq08
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779426, encodeId=82001e7942665, content=<a href='/topic/show?id=48dc20680a' target=_blank style='color:#2F92EE;'>#Affect#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2068, encryptionId=48dc20680a, topicName=Affect)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Tue Dec 31 00:09:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784411, encodeId=4fba1e8441111, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Apr 30 07:09:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012995, encodeId=b067201299574, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Dec 09 03:09:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047108, encodeId=a28b204e10824, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Dec 27 12:09:00 CST 2019, time=2019-12-27, status=1, ipAttribution=)]
    2019-04-30 cmsvly
  3. [GetPortalCommentsPageByObjectIdResponse(id=1779426, encodeId=82001e7942665, content=<a href='/topic/show?id=48dc20680a' target=_blank style='color:#2F92EE;'>#Affect#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2068, encryptionId=48dc20680a, topicName=Affect)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Tue Dec 31 00:09:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784411, encodeId=4fba1e8441111, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Apr 30 07:09:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012995, encodeId=b067201299574, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Dec 09 03:09:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047108, encodeId=a28b204e10824, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Dec 27 12:09:00 CST 2019, time=2019-12-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1779426, encodeId=82001e7942665, content=<a href='/topic/show?id=48dc20680a' target=_blank style='color:#2F92EE;'>#Affect#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2068, encryptionId=48dc20680a, topicName=Affect)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Tue Dec 31 00:09:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784411, encodeId=4fba1e8441111, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Apr 30 07:09:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012995, encodeId=b067201299574, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Dec 09 03:09:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047108, encodeId=a28b204e10824, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Dec 27 12:09:00 CST 2019, time=2019-12-27, status=1, ipAttribution=)]

相关资讯

Rhinology:MP-AzeFlu对过敏性鼻炎控制研究

欧盟已经将过敏性鼻炎(AR)控制作为优先考虑的事情。视觉模拟评分量表(VAS)已经作为AR控制的工具并进入了最新版本的MACVIA-ARIA指南。最近,有研究人员利用VAS在真实世界研究中评估了MP-AzeFlu的效果和安全性。研究包括了431名不小于12岁的参与者,ARIA定义他们为中度到重度AR患者。研究是一个多中心、前瞻性和非干预性研究。研究发现,MP-AzeFlu能够减少平均(SD)VAS

Clin Exp Otorhinolaryngol:长期母乳喂养在预防过敏性鼻炎中的作用分析

环境因素可能影响生命早期过敏性鼻炎的风险。最近,有研究人员调查了分娩方式与母乳喂养持续时间对儿童AR发展的影响。研究包括了1374名儿童,他们被分成AR组和非AR(NAR)组。研究发现,与短期母乳喂养相比(小于6个月),长期母乳喂养(不少于12个月)与AR更低的风险相关(调整后风险比(aOR),0.54;95%CI;0.34-0.88)。AR组的儿童要比NAR组儿童具有更高比例的剖腹产(39.1%

Allergy Asthma Immunol Res:鼻一氧化氮与鼻腔通畅和鼻症状有关

一氧化氮(NO)在上呼吸道和下呼吸道系统中是一种重要的内源性调节因子。最近,有研究人员阐释了中国成年人的鼻NO(nNO)正常范围以及内在的影响因子,并且进一步调查了鼻炎和无症状特应性人群之间的nNO水平差异以及过敏性鼻炎(AR)中诊断nNO的价值。研究包括了1000名成年人,并根据调查问卷和皮刺试验分成不同的亚群。研究发现,nNO和FeNO水平在AR患者中要比健康和无症状特应性参与者显著更高。nN

Otolaryngol Head Neck Surg:鼻甲复位的鼻中隔成形术结果在过敏性鼻炎患者中的前瞻性研究

最近,有研究人员利用验证过的结果和生活质量(QOL)调查工具对过敏性鼻炎患者和非过敏性鼻炎患者就鼻甲复位的鼻中隔成形术结果进行了比较。研究是一个前瞻性的、观察性的群体研究。研究包括了60名症状性鼻中隔偏曲连续性患者,其中30名患有过敏性鼻炎。研究进行的时间为2014年3月到2017年2月。所有的患者均经历了鼻中隔成形术和下鼻甲复位。研究人员发现,NOSE评分、EOB评分和mini-RQLQ评分在2

Chin Med J (Engl):亚太地区哮喘和过敏性鼻炎医生调查

在中国,过敏性鼻炎(AR)和哮喘患病率在过去几十年一直在增加。由于这两种疾病经常共存,ASPAIR研究旨在评估6个亚洲国家中医生对哮喘和鼻炎共存时的观点和治疗模式。研究发现,在接受采访的医生中,约有70%的医生会定期评估其哮喘或AR患者是否有并存疾病的迹象。虽然大多数医生(>90%)意识到了哮喘与AR的共存相比单独其中一种疾病会增加患者的疾病负担,并且还需要额外的治疗,但是大多数医生(96%

Indoor Air:家庭和学校环境与学生鼻炎起始和缓解的关系研究

很少有前瞻性的研究就青少年鼻炎与室内和室外的空气污染的关系进行分析。最近,有研究人员在初中生群体中评估了鼻炎的起始于缓解与家庭和学校的环境之间的关系。研究人员在太远8所学校的1325名学生(11-15岁)中进行了为期2年的调查问卷群体研究。气候和空气污染情况直接通过仪器测量以及采样器采样,并通过多层次的逻辑回归对相关性进行了评估。研究发现,2年间鼻炎和每周鼻炎起始比例分别为26.7%和13.1%。